Article summary
This cohort study (n=346) of clients using Oregon's state-regulated psilocybin services, who received a mean dose of 31.9 mg, found reduced rates of moderate-to-severe depression, anxiety and PTSD symptoms at three months, alongside improved mental well-being and life satisfaction. Serious adverse reactions were uncommon, with four psychedelic-naive participants requiring medical attention during sessions.
Continue to the original publication for the complete article.